checkAd

     109  0 Kommentare Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease - Seite 3

    AGGRASTAT (tirofiban hydrochloride) injection, ZYPITAMAG (pitavastatin) tablets, and Marley Drug are registered trademarks.

    For more information, please contact:
    Dr. Albert D. Friesen
    Chief Executive Officer
    Tel. 888-435-2220
    Fax 204-488-9823
    E-mail: info@medicure.com
    www.medicure.com

    Lesen Sie auch

    SOURCE: Medicure, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/809592/medicure-announces-fda-provides-comp ...


    The Medicure Stock at the time of publication of the news with a fall of -3,33 % to 1,450CAD on TSX Venture stock exchange (22. November 2023, 23:00 Uhr).

    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Accesswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease - Seite 3 WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and …